In the long effort to protect the most vulnerable hearts from their own fragility, a year-long trial presented in New Orleans has quietly shifted the ground beneath a common clinical assumption. The TUXEDO-2 study, following 1,800 diabetic patients across India after coronary stent placement, found that prasugrel — not ticagrelor — more reliably prevented heart attacks, dangerous bleeding, and death over twelve months. Where medicine had long treated two drugs as equals, the data now suggest a meaningful difference, and the question of which pill a patient receives may carry consequences that
Prasugrel Outperforms Ticagrelor in Diabetic Patients Post-Stent, Study Finds
the two should not be used interchangeably
Mark
So this study is saying one blood thinner is better than another for diabetic patients with stents. But aren't these medications already well-established? Why would we not know this?
Mimi
That's the thing—they've been treated as basically equivalent in practice. Cardiologists prescribe whichever one is available or cheaper. This trial is the first large randomized comparison in diabetic patients specifically, and it found measurable differences in real outcomes over a year.
Luke
How big are those differences, though? We're talking 16.57 percent versus 14.23 percent for the main outcome. That's real, but it's not enormous. And this was only in India—different population, different health system.
Mimi
True, but when you're talking about preventing heart attacks and death, even a 2-3 percentage point difference matters at scale. And the death rate gap was bigger—5.03 percent versus 3.67 percent.
Mark
Did they actually watch people take the pills, or are they just assuming compliance?
Luke
They didn't verify it. That's a stated limitation. So we don't know if some people took their medication inconsistently, which could skew the results either way.
Mimi
The lead researcher said they were surprised by the findings—they expected ticagrelor to be as good or better. That suggests this wasn't a predetermined conclusion they were hunting for.
Mark
What happens next? Do guidelines change immediately?
Luke
Unlikely. One trial, even a good one, usually prompts more research before major guideline shifts. But it will probably influence how cardiologists think about the choice, especially in diabetic patients with complex disease.
Mimi
The TUXEDO-2 trial is continuing for five years, so we'll have longer-term data. That might be more persuasive to guideline committees than a one-year snapshot.
Mark
And if this holds up in other countries?
Mimi
Then prasugrel could become the preferred choice for this specific population, which would be a meaningful change in how thousands of patients are treated.
O Pulso
- A foundational assumption in cardiology — that prasugrel and ticagrelor are interchangeable for diabetic stent patients — has been directly contradicted by a large randomized trial.
- The gap in outcomes was consistent across every measured endpoint: fewer heart attacks, less major bleeding, and notably lower death rates in patients receiving prasugrel.
- The lead researcher admitted the results surprised his own team, who had expected ticagrelor to perform at least as well — underscoring how deeply the interchangeability assumption was embedded in clinical thinking.
- The trial's limitations — an open-label design, unverified medication adherence, and an exclusively Indian patient population — temper how quickly these findings can be universally applied.
- A five-year follow-up is underway, and if prasugrel's advantage holds across broader populations, antiplatelet therapy guidelines for diabetic coronary disease patients may require significant revision.
In the long effort to protect the most vulnerable hearts from their own fragility, a year-long trial presented in New Orleans has quietly shifted the ground beneath a common clinical assumption. The TUXEDO-2 study, following 1,800 diabetic patients across India after coronary stent placement, found that prasugrel — not ticagrelor — more reliably prevented heart attacks, dangerous bleeding, and death over twelve months. Where medicine had long treated two drugs as equals, the data now suggest a meaningful difference, and the question of which pill a patient receives may carry consequences that were previously invisible to those prescribing it.
A clinical trial presented at the American Heart Association's Scientific Sessions in New Orleans has challenged one of cardiology's quiet assumptions: that two widely used blood-thinning medications perform equally well in diabetic patients who have received coronary stents. The TUXEDO-2 study tracked 1,800 adults with Type 1 or Type 2 diabetes across 66 hospitals in India, comparing prasugrel and ticagrelor — both P2Y12 inhibitors used alongside aspirin to prevent clotting after stent placement — over the course of one year.
The results consistently favored prasugrel. The combined rate of heart attack, stroke, major bleeding, or death reached 16.57 percent in the ticagrelor group versus 14.23 percent among those taking prasugrel. Death rates showed the sharpest divergence: 5.03 percent for ticagrelor patients compared to 3.67 percent for those on prasugrel. Major bleeding, too, was more common with ticagrelor at 8.41 percent against prasugrel's 7.14 percent.
Lead researcher Dr. Sripal Bangalore of NYU Grossman School of Medicine described the findings as genuinely unexpected, noting that his team had anticipated ticagrelor would perform at least as well. The discovery carries practical weight because current clinical practice treats the two drugs as equivalent — physicians typically prescribe whichever is available or covered by insurance. Bangalore now argues the evidence no longer supports that approach for diabetic patients with complex coronary disease.
The study population was notably high-risk: average age 60, with roughly 79 percent presenting with acute coronary syndrome and approximately 85 percent having blockages in all three major coronary arteries. Conducted entirely in India between 2020 and 2024, the trial benefits from rigorous randomization but may not translate directly to patients with different genetic backgrounds or healthcare contexts. Additional limitations include an open-label design and unverified medication adherence. The trial will continue following participants for five years, offering a longer view of whether prasugrel's early advantage endures — and whether guidelines will ultimately need to follow.
A year-long clinical trial presented at the American Heart Association's Scientific Sessions in New Orleans this week has upended a widespread assumption in cardiology: that two commonly prescribed blood-thinning medications work equally well in diabetic patients who have received stents to open blocked arteries. The TUXEDO-2 study, which tracked 1,800 adults across 66 hospitals in India, found that prasugrel outperformed ticagrelor in preventing heart attacks, blood clots, dangerous bleeding, and death in this high-risk population.
The trial enrolled patients with Type 1 or Type 2 diabetes who had undergone a procedure to restore blood flow to narrowed coronary arteries and received drug-eluting stents—mesh tubes coated with medication to prevent the vessel from re-narrowing. All participants then received one of the two P2Y12 inhibitors, prasugrel or ticagrelor, combined with aspirin as part of dual antiplatelet therapy, the standard approach to prevent clotting after stent placement. Researchers followed the patients for a year, tracking rates of heart attack, stroke, major bleeding, and death.
The numbers told a consistent story favoring prasugrel. The primary composite outcome—any occurrence of heart attack, stroke, bleeding complications, or death—occurred in 16.57 percent of patients taking ticagrelor compared to 14.23 percent of those on prasugrel. Non-fatal heart attacks happened in 5.96 percent of the ticagrelor group versus 5.21 percent in the prasugrel group. Major bleeding events were recorded in 8.41 percent taking ticagrelor and 7.14 percent on prasugrel. Death rates showed the widest gap: 5.03 percent in the ticagrelor group and 3.67 percent in the prasugrel group.
Dr. Sripal Bangalore, the lead researcher and a professor of medicine at NYU Grossman School of Medicine, acknowledged that the findings contradicted the team's initial hypothesis. "We were surprised by the results because we hypothesized that ticagrelor should be as good or perhaps even better than prasugrel," Bangalore said. The discovery matters because current clinical practice treats the two medications as interchangeable—cardiologists and primary care physicians typically prescribe whichever is available or covered by insurance without considering meaningful differences in outcomes. Bangalore emphasized that the evidence now suggests otherwise: "For individuals with Type 1 or Type 2 diabetes and complex coronary disease, there may be an advantage to treatment with prasugrel over ticagrelor, and importantly, the two should not be used interchangeably."
The study population reflected the complexity of diabetic coronary disease. The average age was 60 years, with 71 percent men and 29 percent women. About one quarter were insulin-dependent, roughly 79 percent had acute coronary syndrome, and approximately 85 percent had triple vessel disease—blockages in all three major coronary arteries. The trial ran from 2020 to 2024 and was conducted entirely in India, which introduces both a strength and a limitation: the findings come from a large, well-controlled randomized trial, but they may not directly apply to patients in other countries with different health systems, genetic backgrounds, or disease patterns.
The study does carry methodological constraints worth noting. Patients and their physicians knew which medication was being prescribed, which can introduce bias. Researchers also did not verify whether patients actually took their medications as prescribed, leaving open the possibility that adherence differences between groups affected outcomes. These limitations do not invalidate the findings, but they suggest the need for confirmation in other populations before guidelines change.
The 2025 ACC/AHA guidelines already recommend at least one year of dual antiplatelet therapy for all patients after drug-eluting stent placement. If prasugrel's advantage holds up in future studies, particularly in non-Indian populations, cardiologists may need to revise their approach to selecting which P2Y12 inhibitor to pair with aspirin in diabetic patients—a shift that could affect treatment decisions for thousands of people annually. The TUXEDO-2 trial will continue following participants for five years, potentially offering longer-term data on whether prasugrel's early advantage persists.
Citações Notáveis
We were surprised by the results because we hypothesized that ticagrelor should be as good or perhaps even better than prasugrel.— Dr. Sripal Bangalore, lead researcher, NYU Grossman School of Medicine
For individuals with Type 1 or Type 2 diabetes and complex coronary disease, there may be an advantage to treatment with prasugrel over ticagrelor, and importantly, the two should not be used interchangeably.— Dr. Sripal Bangalore
Quer a matéria completa?
Leia o original em News-Medical.net ↗
Health & Medicine